2 unchanged sentences
Unregistered Sales of Equity Securities and Use of Proceeds
−Removed: On November 30, 2021, the Company announced a share repurchase program approved by the Company's Board of Directors under which the Company was authorized to purchase up to $20.0 million of its common stock. Under this program, during the first three months of 2022 the Company repurchased 649,739 shares at an aggregate fair value of $14.9 million, reflecting an average price per share of $22.92 (excluding the cost of broker commissions). The share repurchase program concluded on March 8, 2022, when the maximum dollar amount was expended. 
+Added: In connection with the Company’s acquisition of the remaining ownership interest of CloudCME as set forth above, the Company issued 208,567 shares of the Company’s common stock at the closing of such acquisition on May 18, 2022, which shares had a value of $4.1 million at the closing. These shares were issued to CloudCME's founder Karl Wilkens as partial payment of the purchase price to Mr.
+Added: Wilkens in exchange for his ownership interest as noted above. These shares were issued in a private placement in reliance upon the exemption set forth in Section 4(a)(2) of the Securities Act.
On March 14, 2022, the Company announced an expansion of the share repurchase program authorized by the Company’s Board of Directors under which the Company may purchase up to an additional $10.0 million of its common stock.
Pursuant to this authorization, repurchases may be made in the open market, including under a Rule 105b-1 plan, through privately negotiated transactions, or otherwise.
−Removed: Under this program, during the first three months of 2022 the Company repurchased 242,647 shares at an aggregate fair value of $5.0 million, reflecting an average price per share of $20.52 (excluding the cost of broker commissions).
+Added: Under this program, during the first six months of 2022 the Company repurchased 402,050 shares at an aggregate fair value of $8.1 million, reflecting an average price per share of $20.19 (excluding the cost of broker commissions).
In addition, any future repurchases under the authorization will be subject to prevailing market conditions, liquidity and cash flow considerations, applicable securities laws requirements (including under Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as applicable), and other factors.
−Removed: The share repurchase program will terminate on the earlier of March 13, 2023 or when the maximum dollar amount has been expended.
−Removed: The table below sets forth activity under the stock repurchase plans for the three months ended March 31, 2022.
+Added: The share repurchase program is scheduled to terminate on the earlier of March 13, 2023 or when the maximum dollar amount has been expended.
+Added: The table below sets forth activity under the stock repurchase plan for the three months ended June 30, 2022.
(a) Total number of shares (or units) purchased
2 unchanged sentences
(d) Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs
−Removed: Month #1 (January 1 - 31)
−Removed: Month #2 (February 1 - February 28)
−Removed: Month #3 (March 1 - March 31)
+Added: Month #1 (April 1 - April 30)
+Added: Month #2 (May 1 - May 31)
+Added: Month #3 (June 1 - June 30)
The weighted average price paid per share of common stock does not include the cost of broker commissions.
HealthStream, Inc.
−Removed: 2022 Cash Incentive Bonus Plan
−Removed: Form of 
−Removed: HealthStream, Inc.
−Removed: Restricted Share Unit Agreement (Performance) under 2016 Omnibus Incentive Plan
−Removed: Form of 
−Removed: HealthStream, Inc.
−Removed: Restricted Share Unit Agreement (Performance) contingent upon approval of 2022 Omnibus Incentive Plan
−Removed: Form of HealthStream, Inc.
−Removed: Restricted Share Unit Agreement (Time Based) contingent upon approval of 2022 Omnibus Incentive Plan
+Added: 2022 Omnibus Incentive Plan
Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
10 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, has been formatted in Inline XBRL
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, has been formatted in Inline XBRL
Management contract of compensatory plan or arrangement
+Added: Incorporated by reference from exhibit 10.1 filed on our Current Report on Form 8-K dated May 31, 2022.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HEALTHSTREAM, INC.
−Removed: April 28, 2022
+Added: July 28, 2022
/s/ Scott A.
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.